When most people think about strength training, they think about muscle: performance, aesthetics or injury recovery. What is often underestimated—even in clinical settings—is its impact on metabolism. Over the past two decades, research has made this one of the strongest arguments for prescribing resistance training as a first-line therapeutic intervention.
Muscle is not just contractile tissue
For decades, skeletal muscle was viewed almost exclusively as a mechanical system: it produces force, enables movement and fatigues. Since the 1990s, physiology has shown that muscle is also an active endocrine organ.
When it contracts, muscle tissue releases signalling molecules known as myokines (such as IL-6, irisin and BDNF) with well-documented systemic effects: reduced chronic inflammation, improved insulin sensitivity, lipid metabolism regulation, and even effects on cognitive function. Each muscle contraction is, to some extent, a biochemical intervention.
Muscle is also the body’s largest glucose sink. At rest, it accounts for around 30% of circulating glucose uptake. During exercise, this can exceed 80%. Increasing functional muscle mass is not only about strength—it is about improving the body’s ability to regulate blood glucose efficiently.
What the evidence says about strength and metabolism
The evidence is consistent enough to support established effects, not hypotheses. Strength training improves insulin sensitivity independently of weight loss, reduces visceral fat (the most cardiometabolically harmful fat), improves markers such as HbA1c and HDL cholesterol, and increases basal metabolic rate through greater metabolically active muscle mass.
All of this without requiring high loads or high intensity. Research also confirms that these benefits can be achieved with moderate, well-designed and progressive protocols—highly relevant for individuals with obesity, hypertension, type 2 diabetes or cardiovascular disease, where strength training is often under-prescribed due to caution rather than evidence.
The challenge of prescribing strength in metabolic populations
The real challenge is individualisation. A 68-year-old patient with type 2 diabetes and overweight cannot follow the same programme as a healthy 45-year-old adult. Appropriate load, intensity and progression require precise baseline data that traditional assessment methods do not always provide.
This is where SUIFF plays a key role. Low-load isometric and dynamic measurement allows clinicians to assess true strength from the first session, safely. Longitudinal tracking turns each session into data: response to stimulus, muscular imbalances, and strength progression over time.
Seeing improvement in numbers and graphs is also one of the strongest motivators for low-adherence populations. It is not just technology—it is continuous clinical support.
Prescribing strength is prescribing metabolic health
In a context where type 2 diabetes and metabolic syndrome continue to rise globally, well-prescribed strength training is one of the most effective interventions in terms of benefit-risk ratio. The challenge is not proving it works—the evidence already does—but making it accessible, safe and measurable.
That is exactly what SUIFF enables in daily clinical practice.
